Third Point Ventures — 2018 Investments

3 investments dated 2018 · listed companies and verified rows first · show all

Cambridge Epigenetixcambridge-epigenetix.com 𝕏Apr 2018

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample.

BiotechDeep TechHealthtechCambridge

Jason Mellad(Executive Officer, Director)inMartin Murphy(Director)Bobby Yerramilli-Rao(Co-founder)Somasundaram Subramaniam(Director)Timothy Rink(Director)Thomas Hulme(Director)

Co-investorsAhren Innovation Capital GV (Google Ventures)New Science Ventures Sequoia Capital Temasek Third Point

PrecisionHawkprecisionhawk.comJan 2018 · $75M

Raleigh, US

Ernest Earon(Director)Michael Chasen(Executive Officer, Director)inRichard Statile(Executive Officer)Brian Bharwani(Executive Officer)Lara Oerter(Executive Officer)Jim Norrodin

Co-investorsMillennium Technology Value Partners NTT DOCOMO Ventures Verizon Ventures Comcast Ventures Intel Capital

RubrYc Therapeuticsrubryc.com inApr 2018

Rubryc discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies for hard-to-drug targets.

AI & Machine LearningBiotechDeep TechSan Ramon, US

Paul Conley(Director)inBill Colston(Executive Officer, Director, Promoter)Jason Hong(Director)Isaac J. Bright(Executive Officer, Director)

Co-investorsPaladin Capital Group Vital Venture Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.